Guillermo Garcia-Manero Selected Research

ponatinib

1/2023	Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
1/2023	Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
5/2022	Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
1/2022	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
1/2022	The cure of leukemia through the optimist's prism.
1/2022	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
1/2021	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
12/2019	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
1/2019	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
12/2018	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guillermo Garcia-Manero Research Topics

Disease

205	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2024 - 01/2002
204	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2024 - 01/2002
128	Neoplasms (Cancer) 03/2024 - 07/2002
105	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2024 - 04/2002
80	Leukemia 01/2023 - 02/2002
64	Philadelphia Chromosome 06/2023 - 04/2002
57	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2023 - 07/2002
32	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 03/2024 - 04/2003
27	Anemia 04/2024 - 04/2002
23	Hematologic Neoplasms (Hematological Malignancy) 01/2024 - 07/2002
22	Thrombocytopenia (Thrombopenia) 04/2023 - 09/2002
18	Blast Crisis (Blast Phase) 01/2023 - 05/2002
18	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 05/2002
17	Primary Myelofibrosis (Myelosclerosis) 04/2024 - 03/2003
17	Infections 11/2023 - 03/2003
15	Residual Neoplasm 12/2022 - 01/2009
15	Acute Promyelocytic Leukemia 01/2022 - 09/2004
14	Pathologic Complete Response 11/2020 - 12/2003
13	Exanthema (Rash) 11/2023 - 03/2003
12	Neutropenia 04/2024 - 06/2003
11	Myeloid Leukemia (Leukemia, Myelocytic) 01/2021 - 03/2003
11	Diarrhea 01/2020 - 08/2002
10	Pneumonia (Pneumonitis) 01/2024 - 01/2004
10	Nausea 11/2023 - 05/2004
10	Disease Progression 04/2023 - 05/2002
9	Fatigue 01/2023 - 04/2003
8	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 04/2003
7	Hypertension (High Blood Pressure) 01/2023 - 11/2015
6	Multiple Myeloma 02/2024 - 03/2003
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 01/2014
6	Leukocytosis (Pleocytosis) 01/2022 - 12/2003
6	Lymphoma (Lymphomas) 01/2021 - 04/2006
6	Fibrosis (Cirrhosis) 10/2018 - 10/2009
6	Splenomegaly 01/2018 - 10/2004
5	Febrile Neutropenia 04/2023 - 11/2012
5	Hemorrhage 01/2023 - 12/2008
5	Cytopenia 01/2023 - 05/2006
5	Iron Overload 01/2023 - 11/2007
5	Myocardial Infarction 01/2023 - 06/2005

Drug/Important Bio-Agent (IBA)

64	Azacitidine (5 Azacytidine)FDA Link 03/2024 - 07/2007
62	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2023 - 05/2002
60	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 05/2002
57	Decitabine FDA Link 02/2024 - 08/2003
47	Tyrosine Kinase InhibitorsIBA 10/2023 - 09/2003
32	venetoclaxIBA 04/2024 - 01/2018
23	Histone Deacetylase InhibitorsIBA 03/2024 - 08/2006
22	Dasatinib (BMS 354825)FDA Link 04/2024 - 12/2007
22	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 06/2002
22	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2023 - 08/2002
22	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2002
22	Lenalidomide (CC 5013)FDA Link 01/2023 - 03/2008
19	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 04/2003
15	fludarabineIBA 11/2022 - 03/2003
15	Clofarabine (Clolar)FDA Link 01/2021 - 10/2003
13	ponatinibIBA 01/2023 - 11/2015
13	Core Binding Factors (Core-Binding Factor)IBA 11/2022 - 12/2008
13	Gemtuzumab (Mylotarg)FDA Link 11/2022 - 01/2002
13	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 04/2003
12	Arsenic Trioxide (Trisenox)FDA Link 01/2022 - 09/2004
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 04/2003
11	blinatumomabIBA 06/2023 - 12/2017
11	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2018
11	Biomarkers (Surrogate Marker)IBA 01/2023 - 07/2011
11	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022 - 04/2004
11	Phosphotransferases (Kinase)IBA 01/2019 - 12/2007
11	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 04/2002
10	Hemoglobins (Hemoglobin)IBA 11/2023 - 04/2002
10	Rituximab (Mabthera)FDA Link 01/2022 - 04/2003
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 01/2009
9	InterferonsIBA 01/2021 - 06/2003
8	Sorafenib (BAY 43-9006)FDA Link 11/2023 - 04/2010
8	Monoclonal AntibodiesIBA 11/2023 - 06/2006
8	Inotuzumab OzogamicinIBA 06/2023 - 03/2015
7	Cladribine FDA LinkGeneric 11/2023 - 08/2005
7	luspaterceptIBA 11/2023 - 01/2020
7	Transaminases (Aminotransferases)IBA 01/2023 - 02/2015
7	ruxolitinibIBA 11/2021 - 03/2015
7	IronIBA 10/2020 - 07/2006
7	nilotinib FDA Link 01/2020 - 12/2007
7	Prednisone (Sone)FDA LinkGeneric 12/2018 - 10/2009
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 04/2009
6	MethyltransferasesIBA 01/2024 - 05/2011
6	BilirubinIBA 11/2023 - 02/2015
6	AnthracyclinesIBA 05/2022 - 08/2002
6	Valproic Acid (Depakote)FDA LinkGeneric 02/2015 - 11/2006
6	Vorinostat FDA Link 12/2012 - 02/2008
5	SB939 compoundIBA 03/2024 - 05/2017
5	EnzymesIBA 01/2023 - 05/2012
5	NucleophosminIBA 01/2023 - 10/2009
5	fms-Like Tyrosine Kinase 3IBA 01/2022 - 11/2016

Therapy/Procedure

257	Therapeutics 03/2024 - 04/2002
72	Drug Therapy (Chemotherapy) 12/2023 - 03/2003
21	Stem Cell Transplantation 01/2023 - 09/2002
16	Induction Chemotherapy 03/2024 - 02/2004
15	Salvage Therapy 01/2023 - 04/2003
9	Hematopoietic Stem Cell Transplantation 05/2024 - 12/2010
7	Transplantation 01/2023 - 10/2007
6	Erythrocyte Transfusion 02/2023 - 01/2016
6	Drug Tapering 11/2021 - 06/2003
5	Immunotherapy 11/2023 - 01/2020